Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Inclusion criteria: * Males and females 18-70 years. Women of childbearing potential must be ready and able (as assessed by investigator) to use simultaneously two reliable methods of birth control, one of which must be highly effective. Highly effective method, per ICH M3(R2) is a method that result in a low failure rate of less than 1% per year when used consistently and correctly. * Diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology (ACR) criteria 1997, at least 4 criteria must be documented, one of which must be a positive anti-dsDNA antibody OR a positive antinuclear antibody (ANA) at screening or around time of start of induction therapy * Lupus Nephritis Class III or IV (International Society of Nephrology (ISN)/Renal Pathology Society (RPS) -2003 classification) with either active or active/chronic disease, co-existing class V permitted, proven by renal biopsy within 3 months prior to screening or during screening if induction therapy has not yet been started * Active renal disease evidenced by proteinuria ≥ 1.0 g/day \[(Uprot/Ucrea) ≥ 1\] * Signed and dated written informed consent Exclusion criteria: * Clinically significant current other renal disease * Glomerular Filtration Rate \<30ml/min/1.73m² * Dialysis within 12m of screening * Antiphospholipid syndrome * Diabetes mellitus poorly controlled or known diabetic retinopathy or nephropathy * Evidence of current or previous clinically significant disease, medical condition or fin…